Adamas Pharmaceuticals
ADMS
ADMS was delisted on the 23rd of November, 2021.
99 hedge funds and large institutions have $150M invested in Adamas Pharmaceuticals in 2019 Q1 according to their latest regulatory filings, with 19 funds opening new positions, 30 increasing their positions, 30 reducing their positions, and 18 closing their positions.
200% more funds holding in top 10
Funds holding in top 10: 1 → 3 (+2)
1% more funds holding
Funds holding: 98 → 99 (+1)
6% more first-time investments, than exits
New positions opened: 19 | Existing positions closed: 18
0% more repeat investments, than reductions
Existing positions increased: 30 | Existing positions reduced: 30
19% less call options, than puts
Call options by funds: $637K | Put options by funds: $786K
27% less capital invested
Capital invested by funds: $207M → $150M (-$56.6M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
AC
Armistice Capital
New York
|
+$18.8M |
| 2 |
SCM
Stonepine Capital Management
Bend,
Oregon
|
+$8.85M |
| 3 |
Millennium Management
New York
|
+$4.84M |
| 4 |
DAM
Deltec Asset Management
New York
|
+$2.7M |
| 5 |
Vanguard Group
Malvern,
Pennsylvania
|
+$2.21M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Invesco
Atlanta,
Georgia
|
-$18M |
| 2 |
Point72 Asset Management
Stamford,
Connecticut
|
-$13.6M |
| 3 |
AllianceBernstein
Nashville,
Tennessee
|
-$10.6M |
| 4 |
Morgan Stanley
New York
|
-$4.91M |
| 5 |
SAM
Sectoral Asset Management
Montreal,
Quebec, Canada
|
-$2.92M |
ADMS Hedge Fund Activity: Q1 2019 in Review
99 of the 4,621 institutional investors tracked by Wall St. Rank reported a position in Adamas Pharmaceuticals (ADMS) for Q1 2019, worth a combined $150M — down 27% from $207M a quarter earlier.
Buyers outnumbered sellers: 19 funds opened new ADMS positions and 18 closed out — a net gain of 1 holder — while 30 added to existing stakes and 30 trimmed.
The largest buyer was Armistice Capital, adding an estimated $18.8M. The largest seller was Invesco, exiting entirely with an estimated $18M sold.
- 99 institutional investors held Adamas Pharmaceuticals (ADMS) as of Q1 2019, up from 98 in Q4 2018.
- Funds reported $150M of Adamas Pharmaceuticals stock for Q1 2019, down 27% quarter-over-quarter.
- 19 funds opened new Adamas Pharmaceuticals positions in Q1 2019 and 18 closed out, a net change of +1 holder.
- The largest Adamas Pharmaceuticals buyer in Q1 2019 was Armistice Capital, an estimated $18.8M added.
- The largest Adamas Pharmaceuticals seller in Q1 2019 was Invesco, an estimated $18M sold.
Based on aggregated 13F filings for Q1 2019.